Literature DB >> 12384333

Interaction of avilamycin with ribosomes and resistance caused by mutations in 23S rRNA.

Christine B Kofoed1, Birte Vester.   

Abstract

The antibiotic growth promoter avilamycin inhibits protein synthesis by binding to bacterial ribosomes. Here the binding site is further characterized on Escherichia coli ribosomes. The drug interacts with domain V of 23S rRNA, giving a chemical footprint at nucleotides A2482 and A2534. Selection of avilamycin-resistant Halobacterium halobium cells revealed mutations in helix 89 of 23S rRNA. Furthermore, mutations in helices 89 and 91, which have previously been shown to confer resistance to evernimicin, give cross-resistance to avilamycin. These data place the binding site of avilamycin on 23S rRNA close to the elbow of A-site tRNA. It is inferred that avilamycin interacts with the ribosomes at the ribosomal A-site interfering with initiation factor IF2 and tRNA binding in a manner similar to evernimicin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384333      PMCID: PMC128742          DOI: 10.1128/AAC.46.11.3339-3342.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  The complete atomic structure of the large ribosomal subunit at 2.4 A resolution.

Authors:  N Ban; P Nissen; J Hansen; P B Moore; T A Steitz
Journal:  Science       Date:  2000-08-11       Impact factor: 47.728

2.  The structural basis of ribosome activity in peptide bond synthesis.

Authors:  P Nissen; J Hansen; N Ban; P B Moore; T A Steitz
Journal:  Science       Date:  2000-08-11       Impact factor: 47.728

3.  Inhibition of the ribosomal peptidyl transferase reaction by the mycarose moiety of the antibiotics carbomycin, spiramycin and tylosin.

Authors:  S M Poulsen; C Kofoed; B Vester
Journal:  J Mol Biol       Date:  2000-12-01       Impact factor: 5.469

4.  VMD: visual molecular dynamics.

Authors:  W Humphrey; A Dalke; K Schulten
Journal:  J Mol Graph       Date:  1996-02

5.  Mutations in ribosomal protein L16 conferring reduced susceptibility to evernimicin (SCH27899): implications for mechanism of action.

Authors:  P V Adrian; W Zhao; T A Black; K J Shaw; R S Hare; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

6.  Structural analysis of RNA using chemical and enzymatic probing monitored by primer extension.

Authors:  S Stern; D Moazed; H F Noller
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

7.  A sparsomycin-resistant mutant of Halobacterium salinarium lacks a modification at nucleotide U2603 in the peptidyl transferase centre of 23 S rRNA.

Authors:  E Lázaro; C Rodriguez-Fonseca; B Porse; D Ureña; R A Garrett; J P Ballesta
Journal:  J Mol Biol       Date:  1996-08-16       Impact factor: 5.469

8.  Presence of variations in ribosomal protein L16 corresponding to susceptibility of enterococci to oligosaccharides (Avilamycin and evernimicin).

Authors:  F M Aarestrup; L B Jensen
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

9.  Effects of mutations in ribosomal protein L16 on susceptibility and accumulation of evernimicin.

Authors:  P M McNicholas; P A Mann; D J Najarian; L Miesel; R S Hare; T A Black
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

10.  Evernimicin (SCH27899) inhibits a novel ribosome target site: analysis of 23S ribosomal DNA mutants.

Authors:  P V Adrian; C Mendrick; D Loebenberg; P McNicholas; K J Shaw; K P Klugman; R S Hare; T A Black
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

View more
  7 in total

1.  Avilamycin and evernimicin induce structural changes in rProteins uL16 and CTC that enhance the inhibition of A-site tRNA binding.

Authors:  Miri Krupkin; Itai Wekselman; Donna Matzov; Zohar Eyal; Yael Diskin Posner; Haim Rozenberg; Ella Zimmerman; Anat Bashan; Ada Yonath
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-19       Impact factor: 11.205

2.  Differential effects of thiopeptide and orthosomycin antibiotics on translational GTPases.

Authors:  Aleksandra Mikolajka; Hanqing Liu; Yuanwei Chen; Agata L Starosta; Viter Márquez; Marina Ivanova; Barry S Cooperman; Daniel N Wilson
Journal:  Chem Biol       Date:  2011-05-27

3.  Bifunctional Nitrone-Conjugated Secondary Metabolite Targeting the Ribosome.

Authors:  Emilianne M Limbrick; Michael Graf; Dagmara K Derewacz; Fabian Nguyen; Jeffrey M Spraggins; Maximiliane Wieland; Audrey E Ynigez-Gutierrez; Benjamin J Reisman; Boris Zinshteyn; Kathryn M McCulloch; T M Iverson; Rachel Green; Daniel N Wilson; Brian O Bachmann
Journal:  J Am Chem Soc       Date:  2020-10-19       Impact factor: 15.419

4.  Combined antimicrobial resistance in Enterococcus faecium isolated from chickens.

Authors:  Odile Petsaris; Fabien Miszczak; Mireille Gicquel-Bruneau; Agnès Perrin-Guyomard; Florence Humbert; Pascal Sanders; Roland Leclercq
Journal:  Appl Environ Microbiol       Date:  2005-05       Impact factor: 4.792

5.  Structural basis for the methylation of G1405 in 16S rRNA by aminoglycoside resistance methyltransferase Sgm from an antibiotic producer: a diversity of active sites in m7G methyltransferases.

Authors:  Nilofer Husain; Karolina L Tkaczuk; Shenoy Rajesh Tulsidas; Katarzyna H Kaminska; Sonja Cubrilo; Gordana Maravić-Vlahovicek; Janusz M Bujnicki; J Sivaraman
Journal:  Nucleic Acids Res       Date:  2010-03-01       Impact factor: 16.971

6.  Structures of the orthosomycin antibiotics avilamycin and evernimicin in complex with the bacterial 70S ribosome.

Authors:  Stefan Arenz; Manuel F Juette; Michael Graf; Fabian Nguyen; Paul Huter; Yury S Polikanov; Scott C Blanchard; Daniel N Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-21       Impact factor: 11.205

7.  Profiling and Identification of Novel Immunogenic Proteins of Staphylococcus hyicus ZC-4 by Immunoproteomic Assay.

Authors:  Lei Wang; Zhi-Wei Wu; Yan Li; Jian-Guo Dong; Le-Yi Zhang; Peng-Shuai Liang; Yan-Ling Liu; Ya-Hua Zhao; Chang-Xu Song
Journal:  PLoS One       Date:  2016-12-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.